HC Wainwright Weighs in on Scholar Rock Q1 Earnings

Key Points

• HC Wainwright maintained its Buy rating and $70 price target, forecasting Scholar Rock losses of $0.76 per share in Q1 2027, narrowing to $0.55 by Q4.
• Scholar Rock’s latest reported quarter beat expectations: loss per share was $0.81 versus an estimated $0.85, while revenue reached $0.57 million against a $0.30 million forecast.
• Despite the earnings beat, shares were down 6.9%; analysts overall held a “Moderate Buy” consensus rating with an average price target of $67.67.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Scholar Rock in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.76) for the quarter. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Scholar Rock's Q2 2027 earnings at ($0.71) EPS, Q3 2027 earnings at ($0.64) EPS and Q4 2027 earnings at ($0.55) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.30 million. During the same quarter in the prior year, the firm earned ($0.90) earnings per share.

A number of other equities research analysts also recently commented on SRRK. UBS Group reaffirmed a "buy" rating on shares of Scholar Rock in a research report on Tuesday, September 15th. Piper Sandler lifted their price objective on Scholar Rock from $60.00 to $75.00 and gave the stock an "overweight" rating in a report on Tuesday, September 15th. TD Cowen reiterated a "buy" rating on shares of Scholar Rock in a research report on Monday, September 14th. Raymond James Financial reiterated a "strong-buy" rating on shares of Scholar Rock in a research report on Tuesday. Finally, Citigroup increased their target price on Scholar Rock from $60.00 to $74.00 and gave the company a "buy" rating in a report on Monday, September 14th. Four research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $67.67.

Scholar Rock Stock Down 6.9%

Shares of Scholar Rock stock opened at $48.00 on Wednesday. Scholar Rock has a twelve month low of $28.97 and a twelve month high of $61.76. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The company's 50 day moving average is $46.83 and its 200 day moving average is $48.22. The company has a market cap of $5.85 billion, a price-to-earnings ratio of -13.91 and a beta of 0.78.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Scholar Rock during the 2nd quarter valued at approximately $522,175,000. Redmile Group LLC boosted its position in shares of Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company's stock worth $445,715,000 after purchasing an additional 3,845,775 shares during the period. Jupiter Topco LLC bought a new position in shares of Scholar Rock in the second quarter worth approximately $123,279,000. Bank of America Corp DE purchased a new stake in shares of Scholar Rock in the second quarter worth $53,474,000. Finally, Eagle Health Investments LP bought a new stake in shares of Scholar Rock during the 2nd quarter valued at $30,540,000. Institutional investors own 91.08% of the company's stock.

Insiders Place Their Bets

In related news, Director Srinivas Akkaraju purchased 146,970 shares of the business's stock in a transaction on Monday, October 26th. The stock was acquired at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the acquisition, the director owned 6,380,517 shares of the company's stock, valued at approximately $265,365,702.03. This trade represents a 2.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 10.30% of the company's stock.

Key Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Scholar Rock reported a Q3 loss of $0.81 per share, beating estimates of $0.85–$0.87, and revenue of $0.57 million, above the $0.30 million forecast. The quarter included the company’s first product revenue, a milestone that may support investor optimism about commercialization. Q3 results Company results and business highlights
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 target. Its 2027 quarterly estimates project progressively smaller losses, from $0.76 per share in Q1 to $0.55 in Q4. Analyst coverage
• Negative Sentiment: Despite the earnings beat and new product revenue, Scholar Rock remains loss-making; HC Wainwright’s estimates still show quarterly losses throughout 2027. This keeps execution and future commercialization important considerations for investors.

Scholar Rock Company Profile

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company's lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients' motor function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.